Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

ATLANTA, Nov. 10 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), a biopharmaceutical firm developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2008 financial results and provided an operational update.

Robert McNally, GeoVax's President and CEO, commented, "We are very pleased with the progress we've made during the third quarter of 2008 and for the year so far, as we've taken steps to address both short-term and long-term goals. We made a shipment of the vaccine to the HIV Vaccine Trials Network during October, which is a significant step in preparation for the largest clinical trial yet to be undertaken by GeoVax and we look forward to HVTN's initiation of the Phase 2a trial later this year. We are also nearing completion of a license with Vivalis S.A., a French biopharmaceutical company, for manufacturing platform technology for the MVA portion of our vaccine that we anticipate will significantly improve the long-term production capabilities for the vaccine."

Financial Results for the Three Months and Nine Months Ended September 30, 2008

The Company recorded a net loss of $722,108 for the three months ended September 30, 2008, compared to $1,165,519 for the same period in 2007. For the nine months ended September 30, 2008, the Company's net loss was $2,688,970 as compared to $3,085,926 in 2007. Net losses for 2008 were partially offset by grant revenues of $1,322,502 and $2,298,571 for the three month and nine month periods, respectively, related to the Company's grant from the National Institutes of Health (NIH) in support of its HIV/AIDS vaccine development activities. As of September 30, 2008, the Company reported cash balances totaling $2,784,706.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operation
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... in Australia through ... retail pharmacies nationwide, TAMPA, Fla., ... leader in pharmacy-based patient care services and,healthlinks.net, a subsidiary of ... a definitive technology licensing and business,consulting agreement, paving the way ...
... to receive funding for preclinical and clinical research projects ... ... ROCKLAND, Mass., Oct. 14 The Michael J. Fox Foundation,for ... five,research teams to speed development of effective therapies for the,under-addressed ...
... Logix, a privately held,biopharmaceutical company focused on using ... drugs, is pleased to announce the,appointment of Keith ... Chief,Executive Officer and to its Board of Directors. ... years of leadership experience in the,biotechnology industry., ...
Cached Biology Technology:Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 2Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 4Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 5Surface Logix Appoints Keith Dionne as President and Chief Executive Officer 2
(Date:4/16/2014)... A 20-year assessment of Nicaragua,s legal, artisanal green sea ... overall catch rates of turtles in what may have ... the Wildlife Conservation Society and University of Florida. , ... than 170,000 green turtles were killed between 1991 and ...
(Date:4/16/2014)... From far away, the top of a leaf looks ... exterior is actually made up of a patchwork of ... in how these cells individually take on their own ... Sampathkumar, and colleagues sought to pinpoint the shape-controlling factors ...
(Date:4/16/2014)... as Kennedy,s disease, spinal and bulbar muscular atrophy (SBMA) is ... weakness and atrophy. Researchers have long considered it to be ... in the spinal cord and brainstem that control muscle movement. ... 16, 2014 online issue of Neuron , a team ...
Breaking Biology News(10 mins):Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3For cells, internal stress leads to unique shapes 2Mutant protein in muscle linked to neuromuscular disorder 2
... We all know that iron deficiencies are dangerous, but ... Our body stores excess iron in various tissues, where ... if not treated before irreversible damage has occurred. Researchers ... Germany, and the European Molecular Biology Laboratory (EMBL) now ...
... discovered the stage at which some of the cells of ... cells and why this occurs. The findings of the ... same until the fourth cleavage (division) of the embryo, are ... the cells of the embryo at first undergo equal, symmetrical ...
... of Ebola virus killed tens of thousands of gorillas ... the May issue of The American Naturalist provide new ... transmission between ape social groups. The study provides hope ... of Ebola on wild apes. , Direct encounters ...
Cached Biology News:Putting an old drug to a new use 2Scientists discover stage at which an embryonic cell is fated to become a stem cell 2Ebola outbreaks killing thousands of gorillas and chimpanzees 2
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
... AmpliTaq Gold® DNA Polymerase is a chemically ... the chemical moiety is attached to the ... and the first ramp of thermal cycling ... annealing temperatures), the enzyme is inactive. The ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
Biology Products: